RARE vs. SANA
Compare and contrast key facts about Ultragenyx Pharmaceutical Inc. (RARE) and Sana Biotechnology, Inc. (SANA).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: RARE or SANA.
Key characteristics
| RARE | SANA | |
|---|---|---|
| YTD Return | 22.84% | 9.56% |
| 1Y Return | 49.62% | -0.78% |
| 3Y Return (Ann) | -14.89% | -43.47% |
| Sharpe Ratio | 0.88 | -0.13 |
| Daily Std Dev | 49.17% | 96.63% |
| Max Drawdown | -82.11% | -93.56% |
| Current Drawdown | -66.89% | -89.72% |
Fundamentals
| RARE | SANA | |
|---|---|---|
| Market Cap | $5.41B | $994.42M |
| EPS | -$7.21 | -$1.14 |
| Total Revenue (TTM) | $481.30M | $0.00 |
| Gross Profit (TTM) | $401.75M | -$19.68M |
| EBITDA (TTM) | -$507.15M | -$217.45M |
Correlation
The correlation between RARE and SANA is 0.44, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
Performance
RARE vs. SANA - Performance Comparison
In the year-to-date period, RARE achieves a 22.84% return, which is significantly higher than SANA's 9.56% return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
RARE vs. SANA - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Ultragenyx Pharmaceutical Inc. (RARE) and Sana Biotechnology, Inc. (SANA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
RARE vs. SANA - Dividend Comparison
Neither RARE nor SANA has paid dividends to shareholders.
Drawdowns
RARE vs. SANA - Drawdown Comparison
The maximum RARE drawdown since its inception was -82.11%, smaller than the maximum SANA drawdown of -93.56%. Use the drawdown chart below to compare losses from any high point for RARE and SANA. For additional features, visit the drawdowns tool.
Volatility
RARE vs. SANA - Volatility Comparison
The current volatility for Ultragenyx Pharmaceutical Inc. (RARE) is 9.33%, while Sana Biotechnology, Inc. (SANA) has a volatility of 19.18%. This indicates that RARE experiences smaller price fluctuations and is considered to be less risky than SANA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
RARE vs. SANA - Financials Comparison
This section allows you to compare key financial metrics between Ultragenyx Pharmaceutical Inc. and Sana Biotechnology, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities